Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia
- 126 Downloads
Recent studies have shown that tumors of relapsed acute myeloid leukemia (AML) present additional genetic mutations compared to the primary tumors. The base excision repair (BER) pathway corrects oxidatively damaged mutagenic bases and plays an important role in maintaining genetic stability. The purpose of the present study was to investigate the relationship between BER functional polymorphisms and AML relapse. We focused on five major polymorphisms: OGG1 S326C, MUTYH Q324H, APE1 D148E, XRCC1 R194W, and XRCC1 R399Q. Ninety-four adults with AML who achieved first complete remission were recruited. Genotyping was performed with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The OGG1 S326C CC genotype (associated with lower OGG1 activity) was observed more frequently in patients with AML relapse [28.9 vs. 8.9%, odds ratio (OR) = 4.10, 95% confidence interval (CI) = 1.35–12.70, P = 0.01]. Patients with the CC genotype exhibited shorter relapse-free survival (RFS). Moreover, the TCGA database suggested that low OGG1 expression in AML cells is associated with a higher frequency of mutations. The present findings suggest that the OGG1 S326C polymorphism increased the probability of AML relapse and may be useful as a prognostic factor for AML relapse risk.
KeywordsAcute myeloid leukemia Polymorphisms OGG1 DNA damage Base excision repair
We are grateful to the experimental contribution of Atsushi Iwasaki and Yasuhiro Nitta.
Compliance with ethical standards
Conflict of interest
The authors declare no competing financial interests.
- 11.Kuriyama K, Tomonaga M, Kobayashi T, Nishikawa K, Ohshima T, Furusawa S, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. In: Hiddemann W, Büchner T, Wörmann, editors. Acute leukemias VII: experimental approaches and novel therapies. New York: Springer; 1998. pp. 901–5.CrossRefGoogle Scholar
- 12.Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Brit J Haematol. 1999;107:69–79.CrossRefGoogle Scholar
- 14.Yamane A, Shinmura K, Sunaga N, Saitoh T, Yamaguchi S, Shinmura Y, et al. Suppressive activities of OGG1 and MYH proteins against G:C to T:A mutations caused by 8-hydroxyguanine but not by benzo[a]pyrene diol epoxide in human cells in vivo. Carcinogenesis. 2003;24:1031–7.CrossRefPubMedGoogle Scholar